

1 Mycobacteria-host interactions in human bronchiolar airway  
2 organoids

3 Nino Iakobachvili<sup>1</sup>, Stephen Adonai Leon Icaza<sup>2</sup>, Kèvin Knoops<sup>1</sup>, Norman  
4 Sachs<sup>3</sup>, Serge Mazères<sup>2</sup>, Roxane Simeone<sup>4</sup>, Antonio Peixoto<sup>2</sup>, Marlène Murris-  
5 Espin<sup>5</sup>, Julien Mazières<sup>5</sup>, Carmen López-Iglesias<sup>1</sup>, Raimond B.G. Ravelli<sup>1</sup>, Olivier  
6 Neyrolles<sup>2,6</sup>, Etienne Meunier<sup>2</sup>, Geanncarlo Lugo-Villarino<sup>2,6</sup>, Hans Clevers<sup>3</sup>,  
7 Céline Cougoule<sup>2,6,7\*</sup>, Peter J. Peters<sup>1,7\*</sup>

8

9 <sup>1</sup> M4i Nanoscopy Division, Maastricht University, Maastricht, Netherlands

10 <sup>2</sup> Institut de Pharmacologie et Biologie Structurale (IPBS), Université de Toulouse,  
11 CNRS, UPS, Toulouse, France

12 <sup>3</sup> Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and  
13 Sciences and University Medical Center, Utrecht, Netherlands

14 <sup>4</sup> Institut Pasteur, Unit for Integrated Mycobacterial Pathogenomics, CNRS  
15 UMR3525, Paris, France

16 <sup>5</sup> Service de Pneumologie, Hôpital Larrey, CHU de Toulouse, Toulouse, France

17 <sup>6</sup>International associated laboratory (LIA) CNRS “IM-TB/HIV” (1167), Toulouse,  
18 France and Buenos Aires, Argentina

19 <sup>7</sup> These authors contributed equally to this work.

20

21 **\*Corresponding authors:**

22 **Email:** [pj.peters@maastrichtuniversity.nl](mailto:pj.peters@maastrichtuniversity.nl) ; [Celine.Cougoule@ipbs.fr](mailto:Celine.Cougoule@ipbs.fr)

23

24

25 **Author Contributions**

26 NI, CC and PJP designed the experiments with the help of CLI, ON, EM and GLV.  
27 NI, SALI and CC performed the experiments with the contribution of KK, RBGR,  
28 SM and AP. SR generated the fluorescent Mtb strains. MME and JM provided the  
29 lung biopsies. HC and NS developed the lung organoid technology. NI, CC and  
30 PJP wrote the manuscript.

31

32 **Competing Interest Statement:** H.C and N.S are inventors on patents related to  
33 organoid technology.

34

35 **Abstract**

36 Tuberculosis, one of the oldest human pathogens remains a major global health  
37 threat. Recent advances in organoid technology offer a unique opportunity to grow  
38 different human “organs” *in vitro*, including the human airway, that faithfully  
39 recapitulate tissue architecture and function. We have explored the potential of  
40 human airway organoids (AOs) as a novel system in which to model tuberculosis  
41 infection. To this end, we adapted biosafety containment level 3-approved  
42 procedures to allow successful microinjection of *Mycobacterium tuberculosis*, the  
43 causative agent of tuberculosis, into AOs. We reveal that mycobacteria infected  
44 epithelial cells with low efficiency, and that the organoid microenvironment was  
45 able to control, but not eliminate the pathogen. We demonstrate that AOs  
46 responded to infection by inducing cytokine and antimicrobial peptide production,  
47 and inhibiting mucins. Given the importance of myeloid cells in tuberculosis  
48 infection, we co-cultured mycobacteria-infected organoids with human monocyte-

49 derived macrophages, and found that these cells were recruited to the organoid  
50 epithelium. We conclude that adult stem cell–derived airway organoids can be  
51 used to model early events of tuberculosis infection and offer new avenues for  
52 fundamental and therapeutic research.

53 **Introduction**

54 Airborne pathogens are a major cause of death worldwide. Respiratory infectious  
55 diseases cause more than 5 million fatalities annually, with tuberculosis (TB)  
56 accounting for one-fifth (WHO Global tuberculosis report 2019). In 2018, TB  
57 caused an estimated 1.5 million deaths, making TB one of the top 10 killers  
58 worldwide, and 25% of the worlds population is thought to be latently infected by  
59 *Mycobacterium tuberculosis* (Mtb) (1).

60 The lung is the entry port for Mtb and the main site of TB disease  
61 manifestation. Mtb-containing droplets navigate through the lung anatomy and  
62 airway functions in order for mycobacteria to establish its replicative niche in the  
63 alveolar space (2, 3). Models of human lung infection are therefore crucial to  
64 increase our understanding of host–pathogen interactions- an essential step  
65 towards new drug development. Whilst conventional 2D cell culture and animal  
66 models have contributed to deciphering key host–pathogen mechanisms at play  
67 during Mtb infection (4), they lack relevance with the human lung.

68 One of the major breakthroughs in the stem cell field is the ability to grow  
69 human ‘organs’ *in vitro*, also known as organoids (5). Human airway organoids  
70 (AOs) are derived from adult stem-cells and composed of a polarized,  
71 pseudostratified airway epithelium containing basal, secretory and multi-ciliated  
72 cells, although they are currently lacking alveolar pneumocytes. They display  
73 functional mucus secretion and ciliate beating (6), therefore constituting a suitable  
74 human system in which to model early steps of host–pathogen interactions (7-9).  
75 We have set out to evaluate the potential of AOs as a model in which to study Mtb  
76 infection. Our data demonstrate that mycobacteria can be readily found in the

77 lumen of AOs with some internalization by airway epithelial cells and overall control  
78 of mycobacterial growth. In response to Mtb infection, we show AOs inducing the  
79 secretion of cytokines and antimicrobial peptides, and the option to model innate  
80 cell recruitment by co-culturing human macrophages with injected AOs.

81

82 **Results & Discussion**

83 Due to the innate cystic structure of AOs, where the pathogen-sensing apical side  
84 faces the lumen, DsRed-expressing H37Rv Mtb (mean  $4271 \pm 834$  CFU/organoid)  
85 was microinjected via a BSL-3-approved custom-made micro-injection system  
86 (Figure 1A). Bacteria could be found in the lumen of AOs and occasionally making  
87 contact with epithelial cells but without causing obvious alterations to organoid  
88 architecture and ultrastructure (Figure 1B-C, Movie S1 and S2). Evident from the  
89 movies is the functional mucociliary system where cilia beat secreted mucus and  
90 cell debris around the lumen.

91 Mtb is known to infect bronchial epithelial cells in 2D conditions (10), and  
92 pneumocytes *in vitro* (11) and *in vivo* (12), but with low efficiency. To identify if Mtb  
93 could infect organoid derived epithelial cells, AOs were dissociated into single  
94 cells, infected with Mtb H37Rv and analyzed by flow cytometry. Approximately  
95 13% and 19% of epithelial cells were found associated with bacteria after 4 h and  
96 24 h of infection, respectively (Figure 1D). Sorted epithelial cells showed that  
97 individual cells harboured Mtb (Figure 1E) suggesting cell invasion by a yet  
98 unknown mechanism. The number of internalised bacteria dropped to 2% when  
99 AOs, which had been infected with Mtb for 7 days, were dissociated into single  
100 cells and analyzed by flow cytometry (Figure 1D). The functioning mucociliary

101 clearance system within AO<sub>s</sub> is likely responsible for reducing mycobacterial  
102 contact with epithelial cells.

103 Mtb has a functional type VII secretion system (ESX-1) encoded by the RD1  
104 locus which is involved in modulating host responses and inducing host cell lysis  
105 (13-16). To determine whether the presence of ESX-1 induced increased epithelial  
106 cell lysis, we quantified cell death by TOPRO-3 incorporation in AO<sub>s</sub> after injection  
107 of wild-type H37Rv or H37Rv $\Delta$ ESX-1 which lacks ESX-1. Neither strain induced  
108 significant epithelial cell death in Mtb-infected AO<sub>s</sub> compared to uninfected ones  
109 (Supp. Figure 1A), indicating that a functional ESX-1 expression does not trigger  
110 increased epithelial cell damage.

111 Next, we investigated mycobacterial survival in AO<sub>s</sub>. Mtb H37Rv  
112 demonstrated a bi-phasic curve (Figure 1F), with a significant decrease of bacterial  
113 load after 7 days followed by an increase at 21 days post-infection. This suggests  
114 an early stage of bacterial control by the AO microenvironment followed by  
115 bacterial adaptation and proliferation. H37Rv $\Delta$ ESX-1 presented a similar pattern  
116 of bacterial growth compared to H37Rv (Figure 1F), demonstrating that Mtb  
117 replicates in AO<sub>s</sub> irrespective of ESX-1 expression.

118 To determine whether AO<sub>s</sub> mounted an inflammatory/antimicrobial  
119 response to Mtb infection, we performed RT-qPCR analysis of Mtb-infected AO<sub>s</sub>  
120 48 h post-injection focusing on cytokine, antimicrobial peptide and mucin  
121 expression (Figure 2A). Significantly induced genes included the expected IL-8  
122 cytokine (Figure 2B)- important for immune cell chemo-attraction *in vivo*. Enhanced  
123 IL-8 secretion in the culture medium of H37Rv and H37Rv- $\Delta$ ESX-1-infected  
124 organoids was confirmed by ELISA (Figure 2C). The antimicrobial peptide  $\beta$ -

125 defensin-1 was also significantly enhanced upon Mtb H37Rv and H37Rv-ΔESX-1  
126 infection (Figure 2B), which might participate in Mtb restriction during early  
127 infection. Interestingly, both Mtb H37Rv and H37Rv-ΔESX-1 significantly  
128 downregulated the expression of mucins, including MUC5B and MUC4 (Figure  
129 2B). Mucin expression and secretion are normally enhanced during inflammation,  
130 and form part of an efficient clearance system for pathogen removal from the  
131 airway (17). Downregulation of mucin expression upon Mtb infection might  
132 facilitate bacilli transit through the airway to reach alveolar macrophages to  
133 establish its replicative niche. For all tested genes, no significant difference was  
134 observed between Mtb H37Rv and H37Rv-ΔESX-1. The H37Rv-ΔESX-1 mutant  
135 seems to induce slightly higher expression of antimicrobial peptides β-defensin-1  
136 and -2, cathelicidin and RNase-7, but this difference was not statistically significant  
137 (Figure 2A).

138 Upon Mtb infection, macrophages mount an inflammatory response  
139 modulating the lung microenvironment (18). AOs were stimulated with the  
140 supernatant of Mtb-infected human macrophages (cmMTB) and analyzed for gene  
141 expression compared to stimulation with the supernatant of non-infected  
142 macrophages (cmCTR). As shown in Figure 2D, among all the tested genes, the  
143 expression of IL-8 and GM-CSF, major cytokines for macrophage control of Mtb  
144 infection, were significantly enhanced in cmMTB-stimulated AOs compared to  
145 those treated with cmCTR, mimicking the paracrine macrophage-epithelial  
146 signaling occurring during lung Mtb infection. Finally, due to the essentiality of  
147 macrophages in TB disease (19), we co-cultured human monocyte-derived  
148 macrophages, alongside mycobacteria-injected organoids, and observed hourly

149 by confocal microscopy over the course of 4 days. Due to the complex nature of  
150 this experiment, it was optimized and set up under BSL-2 conditions using *M. bovis*  
151 BCG. Human macrophages were found to migrate within the collagen matrix and  
152 in some instances, moved towards organoids containing mycobacteria (Movie S3).  
153 Whilst we found no evidence of macrophages being able to traverse the basal side  
154 and enter the organoid lumen to clear mycobacteria, we did observe some  
155 macrophages capturing and ingesting bacteria close to the basal edge of the  
156 organoid (Supp Figure 1B, Movie S3 & S4), resembling the natural process of  
157 macrophage migration to the site of infection and bacterial clearance.

158 We have shown that mycobacteria remain viable for up to 21 days within  
159 the lumen of AOs (Figure 1F) with approximately 2% of bacteria associating with  
160 epithelial cells after the first week of incubation (Figure 1D). During this timeframe,  
161 while AOs integrity remains uncompromised (Figure 1C, Supp Fig 1A, Movie S2),  
162 molecular interactions begin as early as 48 hours after injection with the  
163 upregulation of cytokines and antimicrobial peptides, and the inhibition of mucins  
164 (Figure 2A- C). Within 72 hours, innate immune cells can be recruited to the  
165 surface of infected AOs (Supp Figure 1B, Supp Movie S3, S4). Together, these  
166 data indicate that AOs can be used to study Mtb infection events such as primary  
167 interactions with the airway epithelium.

168 The ability to model these early timeframes in a responsive, multicellular  
169 and functionally similar system to the human airway, but without the complications,  
170 monetary and ethical restrictions of animal research, is revolutionary for the TB  
171 field. The ability to further introduce human macrophages allows functional  
172 modelling of a key cell type and its cellular network, overcoming a major limitation

173 of organoid systems. We believe that this work forms the starting point for  
174 modelling a wide range of human respiratory pathogens, including SARS-CoV-2,  
175 in AOs.

176

177 **Methods**

178 **Ethic statements:** The collection of patient data and tissue for AO generation was  
179 performed according to the guidelines of the European Network of Research Ethics  
180 Committees following European and national law. In the Netherlands and France,  
181 the responsible accredited ethical committees reviewed and approved this study  
182 in accordance with the Medical Research Involving Human Subjects Act. Human  
183 lung tissue was provided by the Primary Lung Culture Facility (PLUC) at MUMC+,  
184 Maastricht, The Netherlands. Collection, storage, use of tissue and patient data  
185 was performed in agreement with the "Code for Proper Secondary Use of Human  
186 Tissue in the Netherlands" (<http://www.fmww.nl>). The scientific board of the  
187 Maastricht Pathology Tissue Collection approved the use of materials for this study  
188 under MPTC2010-019 and formal permission was obtained from the local Medical  
189 Ethical Committee (code 2017-087). The CHU of Toulouse and CNRS approved  
190 protocol CHU 19 244 C and Ref CNRS 205782. All patients participating in this  
191 study consented to scientific use of their material; patients can withdraw their  
192 consent at any time, leading to the prompt disposal of their tissue and any derived  
193 material.

194 Human buffy coats were obtained from volunteers with informed consent via  
195 Sanquin (NVT0355.01) or établissement français du sang (Agreement  
196 21PLER2017-0035AV02).

197 **Organoid culture:** AOs were derived from lung biopsies as described (6).

198 **Bacterial culture and microinjection:** DsRed-WT or -ΔESX-1 H37Rv Mtb strains  
199 were obtained by complementation with the pMRF plasmid containing a DsRed  
200 cassette, and were cultured in the continuous presence of 20 µg/ml of the selective  
201 antibiotic hygromycin and kanamycin respectively (20). Mtb strains and *M. bovis*  
202 BCG were grown and prepared for microinjection as described (18). Bacterial  
203 density was adjusted to OD<sub>600</sub> = 1, and phenol red added at 0.005% to visualize  
204 successful microinjection (21). Injected organoids were allowed to recover for 2 h  
205 at 37 °C, individually collected and re-seeded into fresh matrix for subsequent  
206 analysis.

207 **Microscopy:** For time-lapse imaging, injected organoids were seeded in IBIDI 4  
208 well chambers (IBIDI) and stained with CellMask™ Green Plasma Membrane  
209 Stain (1/1000, Molecular Probes) for 30 min at 37°C. Organoids were washed and  
210 fresh medium containing TOPRO-3 Iodide (1/1000, Molecular Probes) was added.  
211 Organoids were imaged using a FEI CorrSight at Maastricht University or  
212 Andor/Olympus Spinning Disk Confocal CSU-X1 (10x Air 0,4 NA, 3,1 mm WD) at  
213 IPBS. Z-stacks were acquired every hour for the duration of experiments and data  
214 analyzed using Fiji/Image J and IMARIS.

215 For transmission electron microscopy (TEM), injected AO's were fixed in 4% PFA  
216 for a minimum of 3 hours at RT prior to removal from the containment lab and  
217 embedding in epon blocks as described in (22). TEM data was collected  
218 autonomously as virtual nanoscopy slides on a 120kV FEI Tecnai Spirit T12  
219 Electron Microscope equipped with an Eagle CCD camera (23).

220 **Colony forming unit (CFU) assay:** 4 to 6 Mtb-injected organoids were collected,  
221 washed in PBS, seeded into 24-well plates and cultured in complete AO medium  
222 for 7–21 days. At the relevant timepoint, organoids were lysed in 100  $\mu$ l of 10%  
223 Triton X100 in water, serial dilutions were plated on 7H11 agar plates and cultured  
224 for 3 weeks at 37 °C.

225 **RT-qPCR:** Uninfected control and Mtb-infected AO's (15 per condition) were  
226 collected at 48 h post-infection, lysed in 1 ml of TRIzol Reagent (Invitrogen) and  
227 stored at -80 °C for 2 days. As positive controls, AO's were stimulated with 0.02  
228  $\mu$ g/ml of human IL-1 $\beta$  (Invivogen) or 0.1  $\mu$ g/ml of IFN $\gamma$  (PeproTech) for 48 h. Total  
229 RNA was extracted using the RNeasy mini kit (Qiagen) and retrotranscribed (150  
230 ng) using the Verso cDNA Synthesis Kit (Thermo Scientific). mRNA expression  
231 was assessed with an ABI 7500 real-time PCR system (Applied Biosystems) and  
232 the SYBRTM Select Master Mix (ThermoScientific). Relative quantification was  
233 determined using the  $2^{-\Delta\Delta Ct}$  method and normalized to GAPDH. Primer  
234 sequences are provided in Table 1.

235 **Enzyme-linked immunoabsorbent assay:** Between 20–30 organoids were  
236 embedded in fresh BME Cultrex and cultured with 800  $\mu$ L complete media. After  
237 48 h, supernatant was collected, sterilized through double 0.22  $\mu$ m filters and  
238 stored at -80 °C until analysis. IL-8 ELISA was performed according to  
239 manufacturer instructions (Qiagen).

240 **Flow cytometry and cell sorting:** Organoids were washed out of Matrigel and  
241 dissociated into single cells using TrypLE for 5 min at 37 °C. A minimum of  $5 \times 10^5$   
242 cells/ml were incubated with Mtb at an MOI of 10 in complete organoid media. After  
243 4 or 24 h for single cells, or 7 days for whole intact organoids, samples were

244 washed with PBS, stained with CellMask Deep Red (1:30.000) and fixed in 4%  
245 paraformaldehyde overnight at 4 °C. Cells were pelleted and resuspended in PBS  
246 supplemented with 2% FCS. Samples were filtered just before analysis and sorted  
247 using a BD FACS ARIA Fusion.

248 **CmMTB preparation and Macrophage co-cultures:** Monocytes were enriched  
249 using RosetteSep human monocyte enrichment cocktail (Stem Cell Technologies)  
250 and purified by density gradient centrifugation. Monocytes were differentiated into  
251 macrophages by addition of 5 ng/ml macrophage colony stimulating factor (Sigma  
252 Aldrich) for 6 days. cmCTR and cmMTB were prepared and used as previously  
253 described (18). Organoids were stained with CellMask Deep Red plasma  
254 membrane dye as previously described, and macrophages stained with 20 µM  
255 CellTracker Blue CMAC dye (ThermoFisher Scientific) for 1 h in serum-free media.  
256 Microinjected organoids and macrophages were resuspended in freshly prepared  
257 Rat Tail Collagen type 1 (Thermofisher, 1 mg/ml) and polymerized in a 4-well,  
258 glass-bottom µ-slide (Ibidi) at 37 °C for 30 min, and imaged for 96 h under a FEI  
259 CorrSight microscope.

260

## 261 **Acknowledgments**

262 Authors acknowledge C. Kuo (Stanford University, USA) for the stable expressing  
263 Rspo1-Fc cell line and the Hubrecht Institute for the stable expressing Noggin cell  
264 line; Genotoul TRI-IPBS core facility for flow cytometry and imaging, in particular  
265 Näser and E. Vega; IPBS BSL3 facilities, in particular C. Verollet for technical  
266 support. Authors also acknowledge the Microscopy CORE lab and PLUC facility  
267 at Maastricht University. This work was supported by grants from Campus France

268 PHC Van Gogh (40577ZE to GL-V), the Agence Nationale de la Recherche (ANR-  
269 15-CE15-0012 (MMI-TB)) to GL-V, FRM “Amorçage Jeunes Equipes”  
270 (AJE20151034460 to EM), ERC StG 693 (INFLAME 804249 to EM), ATIP to EM,  
271 ZonMW 3R’s (114021005) to PJP, the Nuffic Van Gogh Programme (VGP.17/10  
272 to NI), and by the LINK program from the Province of Limburg, the Netherlands..  
273

## 274 **References**

- 275 1. Houben RM & Dodd PJ (2016) The Global Burden of Latent Tuberculosis Infection: A Re-  
276 estimation Using Mathematical Modelling. *PLoS Med* 13(10):e1002152 .
- 277 2. Corleis B & Dorhoi A (2020) Early dynamics of innate immunity during pulmonary  
278 tuberculosis. *Immunol Lett* 221:56-60 .
- 279 3. Torrelles JB & Schlesinger LS (2017) Integrating Lung Physiology, Immunology, and  
280 Tuberculosis. *Trends Microbiol* 25(8):688-697 .
- 281 4. Fonseca KL, Rodrigues PNS, Olsson IAS, & Saraiva M (2017) Experimental study of  
282 tuberculosis: From animal models to complex cell systems and organoids. *PLoS Pathog*  
283 13(8):e1006421 .
- 284 5. Rossi G, Manfrin A, & Lutolf MP (2018) Progress and potential in organoid research. *Nat  
285 Rev Genet* 19(11):671-687 .
- 286 6. Sachs N, *et al.* (2019) Long-term expanding human airway organoids for disease modeling.  
287 *The EMBO journal* 38(4) .
- 288 7. Dutta D & Clevers H (2017) Organoid culture systems to study host-pathogen interactions.  
289 *Curr Opin Immunol* 48:15-22 .
- 290 8. Iakobachvili N & Peters PJ (2017) Humans in a Dish: The Potential of Organoids in  
291 Modeling Immunity and Infectious Diseases. *Frontiers in microbiology* 8:2402 .
- 292 9. Pleguezuelos-Manzano C, *et al.* (2020) Mutational signature in colorectal cancer caused  
293 by genotoxic pks(+) *E. coli*. *Nature* 580(7802):269-273 .
- 294 10. Reuschl AK, *et al.* (2017) Innate activation of human primary epithelial cells broadens the  
295 host response to *Mycobacterium* tuberculosis in the airways. *PLoS Pathog*  
296 13(9):e1006577 .
- 297 11. Ryndak MB, Singh KK, Peng Z, & Laal S (2015) Transcriptional profile of *Mycobacterium*  
298 tuberculosis replicating in type II alveolar epithelial cells. *PLoS One* 10(4):e0123745 .
- 299 12. Cohen SB, *et al.* (2018) Alveolar Macrophages Provide an Early *Mycobacterium*  
300 tuberculosis Niche and Initiate Dissemination. *Cell Host Microbe* 24(3):439-446 e434 .
- 301 13. Houben D, *et al.* (2012) ESX-1-mediated translocation to the cytosol controls virulence of  
302 mycobacteria. *Cell Microbiol* 14(8):1287-1298 .
- 303 14. Tiwari S, Casey R, Goulding CW, Hingley-Wilson S, & Jacobs WR, Jr. (2019) Infect and  
304 Inject: How *Mycobacterium* tuberculosis Exploits Its Major Virulence-Associated Type VII  
305 Secretion System, ESX-1. *Microbiol Spectr* 7(3) .
- 306 15. van der Wel N, *et al.* (2007) *M. tuberculosis* and *M. leprae* translocate from the  
307 phagolysosome to the cytosol in myeloid cells. *Cell* 129(7):1287-1298 .

308 16. Sanne van der Nieuw, *et al.* (2020) Both adaptive immunity and IL-1R1 dependent signals  
309 improve clearance of cytosolic virulent mycobacteria in vivo. *BioRxiv*.  
310 17. Whitsett JA & Alenghat T (2015) Respiratory epithelial cells orchestrate pulmonary innate  
311 immunity. *Nat Immunol* 16(1):27-35 .  
312 18. Lastrucci C, *et al.* (2015) Tuberculosis is associated with expansion of a motile, permissive  
313 and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis. *Cell Res*  
314 25(12):1333-1351 .  
315 19. Cadena AM, Flynn JL, & Fortune SM (2016) The Importance of First Impressions: Early  
316 Events in *Mycobacterium tuberculosis* Infection Influence Outcome. *mBio* 7(2):e00342-  
317 00316 .  
318 20. Simeone R, *et al.* (2015) Cytosolic access of *Mycobacterium tuberculosis*: critical impact  
319 of phagosomal acidification control and demonstration of occurrence in vivo. *PLoS*  
320 *Pathog* 11(2):e1004650 .  
321 21. Bartfeld S & Clevers H (2015) Organoids as Model for Infectious Diseases: Culture of  
322 Human and Murine Stomach Organoids and Microinjection of *Helicobacter pylori*. *J Vis*  
323 *Exp* (105).  
324 22. Lamers MM, *et al.* (2020) SARS-CoV-2 productively infects human gut enterocytes.  
325 *Science* 369(6499):50-54 .  
326 23. Faas FG, *et al.* (2012) Virtual nanoscopy: generation of ultra-large high resolution electron  
327 microscopy maps. *J Cell Biol* 198(3):457-469 .  
328  
329

330 **Figures**

331 **Figure 1. Human airway organoids (AOs) infected with Mtb.** (A) Experimental  
332 scheme and bright-field image of the microinjection. (B) Confocal microscopy  
333 of DsRed-expressing H37Rv inside AOs, 4 days post-infection. Nuclei are labeled  
334 with DAPI (blue); cellular membranes with CellMask green (green). (C)  
335 Transmission electron microscopy at one week post-infection showing H37Rv  
336 within the organoid lumen. Lower panels show magnifications of the boxed areas  
337 in the upper image. (D) Quantification of cells associated with H37Rv after 4 (left)  
338 or 24 hours (middle) incubation with AOs-derived single cells or 7 days incubation  
339 in whole organoids (right) (E) Representative images of sorted epithelial cells with  
340 intracellular DsRed-expressing H37Rv, scale bars = 5 $\mu$ m. (F) CFU counts from  
341 individual organoids on the day of microinjection (day 0), 7 and 21 days post-

342 infection. Each dot represents one organoid. Lines indicate median CFU counts.  
343 The experiment was performed at least four times independently. \*\*\*P < 0.001 by  
344 a two-tailed Mann-Whitney test.

345 **Figure 2. Mtb-induced host responses in AOs.** (A) Heat map displaying  
346 modulation of cytokines, antimicrobial peptides and mucins in AOs in response to  
347 mycobacterial injection (H37Rv and H37Rv $\Delta$ RD1) compared to mock-injected  
348 organoids. As positive controls, AOs were treated with recombinant IL-1 $\beta$  and  
349 IFN $\gamma$ . (B) Statistically significant expression changes of IL-8,  $\beta$ -Defensin-1, MUC5B  
350 and MUC4 as determined by RT-qPCR at 48 h post-infection. \*p < 0.05 by  
351 Wilcoxon matched-pairs signed rank test. (C) ELISA quantification of IL-8 secretion  
352 by H37Rv- or H37Rv- $\Delta$ RD1-infected AOs at 48 h post-infection. IL-8 secretion in  
353 H37Rv-infected AOs was almost significantly ( $p=0.053$  by two-tailed Wilcoxon  
354 matched-pairs signed rank test), recIL-1 $\beta$ -treated AOs (recIL-1 $\beta$ ) was used as  
355 positive control. (D) Statistically significant expression changes of IL-8 and GM-  
356 CSF as determined by RT-qPCR at 72 h after conditioning with cmCTR and  
357 cmMTB, defined as conditioned media from non-infected and Mtb-infected  
358 macrophages, respectively.

359

360 **Supplementary Figure 1. Cell death and macrophage recruitment in**  
361 **mycobacteria-infected AOs. Related to Figure 1.**

362 (A) AOs (red) were injected with PBS (as a control) or mycobacteria (green),  
363 stained with ToPRO3 (blue) and imaged for 4 days. ToPRO3 incorporation, and  
364 therefore epithelial cell death, was quantified using Fiji and plotted on the right

365 panel. (B) AO<sub>s</sub> microinjected with GFP-expressing *M. bovis* BCG were embedded  
366 with human monocyte-derived macrophages in collagen and imaged hourly by  
367 confocal microscopy for 5 days. AO<sub>s</sub> and macrophages were stained with  
368 CellMask Deep Red (top row) whilst macrophages were weakly stained using Cell  
369 tracker CMAC blue allowing for segmentation in IMARIS (bottom row), arrows  
370 indicate bacteria (green) passing through the epithelial cell wall (red) and  
371 interacting with macrophages (blue). Scale bar = 20 $\mu$ m.

372

373 **Supplementary Movie S1. Injected mycobacteria survive in the organoid**  
374 **lumen. Related to Figure 1.**

375 3D reconstruction of an Mtb-infected AO<sub>s</sub> 4 days post-infection. DsRed-expressing  
376 bacteria are visible in red, epithelial cell membranes are stained with Cell Mask  
377 Green, and nuclei with DAPI (blue).

378

379 **Supplementary Movie S2. AO infection with WT and  $\Delta$ RD1 H37Rv Mtb**  
380 **strains. Related to Figure 1.**

381 Time-lapse microscopy of PBS- (left panel), H37Rv- (middle panel) and  $\Delta$ RD1  
382 H37Rv- (right panel) injected organoids (stained with Cell Mask Green) over 48  
383 hours.

384

385 **Supplementary Movie S3. Macrophages are recruited to AO<sub>s</sub> for bacterial**  
386 **clearance. Related to Figure 2 and supplementary Figure 1.**

387 Macrophages migrating to AOs in brightfield (left) and confocal microscopy (right).  
388 AOs membranes are stained with CellMask Deep Red, mycobacteria are  
389 expressing GFP and macrophages are stained with CellTracker CMAC blue.

390

391 **Supplementary Movie S4. 3D reconstruction showing frame wise interaction**  
392 **of macrophages with the AO surface and internal mycobacteria. Related to**  
393 **Figure 2 and supplementary Figure 1.**

394 IMARIS rendering of supplementary movie S3 showing macrophages (blue)  
395 migrating to organoids (red) and cleaning up bacteria (green) from within the  
396 organoid.

397

## 398 **Tables**

399 **Table 1.** List of primers used for RT-qPCR experiments on airway organoids.

Gene	Primers 5'-3'	Reference
<b>Cytokines and chemokines</b>		
<b>CCL5 (NM_002985)</b>	F- CCTCATTGCTACTGCCCTCT R- CGGGTGACAAAGACGACTGC	In-house
<b>GM-CSF (NM_000758)</b>	F- CCTGAACCTGAGTAGAGACACT R- CCTTGAGCTTGGTGAGGCTG	In-house
<b>IL-1<math>\beta</math> (NM_000576)</b>	F- AGCTACGAATCTCCGACCAC R- GGGAAAGAAGGTGCTCAGGTC	In-house
<b>IL-6 (NM_000600.5)</b>	F: ACTCACCTCTTCAGAACGAATTG R: CCATCTTGGAAAGGTTTCAGGTTG	PrimerBank
<b>IL-8 (NM_000584)</b>	F- TACTCCAAACCTTCCACCCCC R- CTTCTCCACAACCCCTTGCA	In-house
<b>IP-10 (NM_001565)</b>	F- GTGGCATTCAAGGAGTACCTC R- GATTAGACATCTCTCACCC	In-house
<b>Antimicrobial peptides</b>		
<b><math>\beta</math> defensin 1 (NM_005218)</b>	F- ATGGCCTCAGGTGGTAACCTTC R- GGTCACTCCCAGCTCACTTG	In-house
<b><math>\beta</math> defensin 2 (NM_004942)</b>	F- ATAGGCGATCCTGTTACCTGC R- CCTCCTCATGGCTTTGCAG	In-house
<b><math>\beta</math> defensin 3 (NM_018661)</b>	F- TGGGGTGAAGCCTAGCAG R- ACTTGCCGATCTGTTCTCC	In-house
<b><math>\beta</math> Defensin 4 (NM_080389.3)</b>	F: TGCCGGAAGAAATGTCGCA R: CGACTCTAGGGACCAGCAC	In-house
<b>Cathelicidin LL37 (NM_004345)</b>	F- ATGCTAACCTCTACCGCCTCC R- TCACCAGCCCCGTCTTCTTG	In-house

<b>Hepcidin (NM_021175)</b>	F- GTTTCCCACAAACAGACGGG R- AGATGGGAAAGTGGGTGTC	In-house
<b>Lactoferrin (NM_002343)</b>	F- CCCCTACAAACTGCGACCTG R- CAGACCTTGCAGTTCGTTCAG	In-house
<b>RNAse 7 (NM_032572)</b>	F- GGAGTCACAGCACGAAGACCA R- GGCTTGGCACTGACTGGGATC	In-house
<b>Mucins</b>		
<b>MUC4 (NM_018406.7)</b>	F: CTCAGTACCGCTCCAGCAG R: CCGCCGCTTCATGGTCAG	In-house
<b>MUC5AC (NM_001304359.2)</b>	F: CCAGTCCTGCCTTGTACGG R: GACCCTCTCTCAATGGTGC	In-house
<b>MUC5B (NM_002458.3)</b>	F: GCCCACATCTCCACCTATGAT R: GCAGTTCTCGTTGTCCGTCA	PrimerBank
<b>Housekeeping</b>		
<b>GAPDH (NM_002046)</b>	F-CTCCAAAATCAAGTGGGCGATG R-GGCATTGCTGATGATCTTGAGGC	In-house

400


401

402


403

404

# Iakobachvili et al. Figure 1




# Iakobachvili et al. Figure 2



# Iakobachvili et al. Supplementary Figure 1

A



B

